演題詳細

ポスター / Poster

ポスター 51 (Poster 51) :小児血液 (Pediatric Blood)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F エメラルドABCD)
座長・司会
遠藤 幹也 (Mikiya Endo):1
1:岩手医科大学 小児科学講座
 
前へ戻る

Seven cases with E. coli asparaginase - associated pancreatitis -a single institute experience-

演題番号 : PS-1-384

安井 昌博 (Masahiro Yasui):1、佐藤 真穂 (Maho Sato):1、近藤 統 (Osamu Kondo):1、澤田 明久 (Akihisa Sawada):1、樋口 紘平 (Kohei Higuchi):1、清水 真理子 (Mariko Shimizu):1、井坂 華奈子 (Kanako Isaka):1、井上 雅美 (Masami Inoue):1

1:Dept. Hematology/Oncology, Osaka Medical Center for Maternal Child Health., Japan

 

(Background)Escherichia coli (E. coli) asparaginase, a key drug for acute lymphoblastic leukemia (ALL), chronic active EB virus infection (CAEBV) and other hematologic disorders, is well known as a cause of drug - induced pancreatitis. (Patients and methods)We retrospectively analyzed 7 pediatric patients (median ages 8; range, 4-15 years, male 3 and female 4, 4 ALL, 2 CAEBV, 1 AML) with asparaginase - associated pancreatitis (AAP) between 2010 and 2013. (Results)AAP developed on median day 7 (range 1-15) after last E. coli asparaginase administration as a component of combination chemotherapy. Three out of 7 patients had hypercholesterolemia and hypertriglyceridemia. Two patients developed pseudocyst and drainage operation was done to avoid progression of pancreatic damage. All patients has been undergoing chemotherapy without using E. coli asparaginase or performed stem cell transplantation after AAP. One patient died of infectious disease and other six patients are alive in CR or stable disease. (Conclusions)Although the mechanism of AAP is not clarified yet, however, our experience suggests that lipid metabolism abnormality may play an important role. Careful observation is warranted to perform E. coli asparaginase treatment. Effective methods to avoid AAP should be developed for safe use of E. coli asparaginase.

前へ戻る